

CITATION REPORT

List of articles citing

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

DOI: 10.1007/s40262-017-0528-2

Clinical Pharmacokinetics, 2017, 56, 1381-1390.

Source: <https://exaly.com/paper-pdf/66166996/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
67	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 104, 31-41	5.1	64
66	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. <i>Postgraduate Medicine</i> , 2018 , 130, 381-393	3.7	17
65	Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1314-1323	2.9	41
64	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1571-1580	6.2	56
63	Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 371-377	5.5	9
62	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 343-351	5.4	7
61	Semaglutide: First Global Approval. <i>Drugs</i> , 2018 , 78, 275-284	12.1	32
60	New Glucose-Lowering Agents for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2018 , 25, 149-157	4.7	10
59	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. <i>Advances in Therapy</i> , 2018 , 35, 531-544	4.1	7
58	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 610-619	6.7	69
57	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 889-897	6.7	114
56	Semaglutide once-weekly: improved efficacy with a new safety warning. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1061-1072	3.8	7
55	Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. <i>Journal of the American Association of Nurse Practitioners</i> , 2018 , 30, S29-S42	1	2
54	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2210-2219	6.7	44
53	Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2426-2434	6.7	8
52	Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. <i>Diabetes Therapy</i> , 2018 , 9, 1533-1547	3.6	15
51	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1529-1538	6.2	13

50	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 136-145	2.1	26
49	Polyethylene glycol loxanatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2714-2720	3.8	5
48	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 2985-2996	4.4	6
47	Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 142, 411-420	5.7	21
46	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <i>Diabetes Therapy</i> , 2019 , 10, 1645-1717	3.6	17
45	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <i>Diabetes and Metabolism</i> , 2019 , 45, 409-418	5.4	54
44	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 515-527	18.1	99
43	Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. <i>Molecular Pharmaceutics</i> , 2019 , 16, 2278-2295	5.6	27
42	Diabetic Pharmacotherapies in Kidney Disease. 2019 , 49-74		
41	GREATER COMBINED REDUCTIONS IN HbA _{1c} AND WEIGHT WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. <i>Endocrine Practice</i> , 2019 , 25, 589-597	3.2	6
40	Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 731-738	4.4	14
39	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , 2019 , 10, 155	5.7	181
38	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019 , 20, 805-815	10.6	33
37	Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease. <i>Nurse Practitioner</i> , 2019 , 44, 20-28	0.4	
36	Incretins in obesity and diabetes. <i>Annals of the New York Academy of Sciences</i> , 2020 , 1461, 104-126	6.5	32
35	A Review on Semaglutide: An Oral Glucagon-Like Peptide-1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2020 , 11, 1965-1982	3.6	12
34	A proopiomelanocortin-derived peptide sequence enhances plasma stability of peptide drugs. <i>FEBS Letters</i> , 2020 , 594, 2840-2866	3.8	1
33	Semaglutide injection for the treatment of adults with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 675-684	3.8	3

32	Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.. <i>RSC Advances</i> , 2020 , 10, 4725-4732	3.7	0
31	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	27
30	Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. <i>Advances in Therapy</i> , 2021 , 38, 550-561	4.1	3
29	GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. <i>Molecular Metabolism</i> , 2021 , 46, 101102	8.8	108
28	Recent advances in treatment of haemodialysis. <i>Journal of the Royal Society of Medicine</i> , 2021 , 114, 30-37.	3.3	3
27	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1049-1059	6.2	4
26	Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
25	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021 , 12, 645507	5.7	5
24	Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 1667-1675	15.5	4
23	Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23 Suppl 3, 40-52	6.7	4
22	Safety of injectable semaglutide for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 785-798	4.1	5
21	Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 998-1005	6.7	31
20	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. <i>Annals of Translational Medicine</i> , 2018 , 6, 129	3.2	3
19	Clinical potential of treatment with semaglutide in type 2 diabetes patients. <i>Drugs in Context</i> , 2019 , 8, 212585	5.2	2
18	Pharmacotherapy in pediatric obesity: current evidence and landscape. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021 , 28, 55-63	4	4
17	Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	1
16	Clinical review of subcutaneous semaglutide for obesity.. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 ,	2.2	1
15	Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design. <i>Hypertension</i> , 2020 , 76, 420-431	8.5	3

14	Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. <i>Clinical Pharmacokinetics</i> , 2022 , 61, 1057-1067	6.2	2
13	Pharmacologic Weight Management in the Era of Adolescent Obesity.		0
12	Derivatization with fatty acids in peptide and protein drug discovery.		0
11	Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. 2022 , 239, 108277		1
10	Future perspectives on peptide therapeutics. 2022 , 699-726		0
9	GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?. 2022 , 24, 867-884		0
8	Seeing the Light: Improving Diabetic Retinopathy Outcomes by Bringing Screening to the Dialysis Clinic. 2022 , 3, 1474-1476		0
7	Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. 2022 , 10, 2586		0
6	Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience. 2022 , 13, 377		0
5	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. 2022 , 146, 1882-1894		1
4	Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GIP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. 2023 , 12, 145		0
3	Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. 2023 , 18, e0278685		0
2	Efficacy and safety of semaglutide for weight management: evidence from the STEP program. 2022 , 134, 5-17		0
1	Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. 2023 , 1221, 123688		0